Catalent To Acquire Cell- and Gene-Therapy CDMO MaSTherCell for $315 MBy
Catalent has agreed to acquire MaSTherCell Global, a cell and gene therapy CDMO based in Gosselies, Belgium and Houston, Texas for $315 million in cash.
Founded in 2011, MasTherCell provides development and manufacturing services of autologous and allogeneic cell therapies as well as a variety of related analytical services. Its experience includes therapies based on chimeric antibody receptor-engineered T cells, T cell receptors, tumor-infiltrating lymphocytes, and mesenchymal stem cells.
MaSTherCell has a 25,000-square-foot facility in Gosselies, Belgium that provides clinical development and manufacturing services for cell and gene therapies. Construction is in progress for a dedicated 60,000 square-foot adjacent commercial-scale production and fill–finish facility, which is scheduled to open in the fall of 2021. The new facility is expected to ultimately add over 250 new jobs to the company’s current team of over 240 employees.
As part of the overall transaction, Catalent will also acquire a 32,000-square-foot US facility in Houston, Texas, which, upon completion of validation activities, will focus on development-scale projects and will employ a team of over 50 experts before the end of 2020.
The transaction is expected to close in the current, third quarter of Catalent’s 2020 fiscal year and is subject to customary closing conditions. Upon closing, MaSTherCell’s 240 employees, including its leadership team, will become part of the Catalent Biologics business.